SCHEMBL4320377

SCHEMBL4320377

Cc1ccsc1C(=O)Nc1cc(CN2CCC(CCO)CC2)ccc1C=Cc1n[nH]c2ccccc12

nearest known ligand 0.70

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ AURKA O14965 4/20 0.70
▸ AURKB Q96GD4 4/20 0.70
▸ HTR1A P08908 1/20 0.41
▸ DRD2 P14416 1/20 0.41
▸ HTR2A P28223 1/20 0.41
▸ PARP1 P09874 1/20 0.39
▸ GSK3B P49841 5/20 0.39
▸ CDK5 Q00535 1/20 0.37
▸ CDK5R1 Q15078 1/20 0.37
▸ ACKR3 P25106 1/20 0.36
▸ ACHE P22303 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ PDGFRB P09619 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ NPC1 O15118 1/20 0.36
▸ RAB9A P51151 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4320372 1.00 AURKA (0.70) AURKAAURKBHTR1ADRD2HTR2A
SCHEMBL4321884 0.94 AURKA (0.66) AURKAAURKBHTR1ADRD2HTR2A
SCHEMBL4321892 0.94 AURKA (0.66) AURKAAURKBHTR1ADRD2HTR2A
SCHEMBL4326126 0.91 AURKA (0.74) AURKAAURKBHTR1ADRD2HTR2A
SCHEMBL4326122 0.91 AURKA (0.74) AURKAAURKBHTR1ADRD2HTR2A
SCHEMBL4313205 0.91 AURKA (0.74) AURKAAURKBPARP1CDK5CDK5R1
SCHEMBL4313197 0.91 AURKA (0.74) AURKAAURKBPARP1CDK5CDK5R1
SCHEMBL4313646 0.90 AURKA (0.72) AURKAAURKBHTR1ADRD2HTR2A
SCHEMBL4313639 0.90 AURKA (0.72) AURKAAURKBHTR1ADRD2HTR2A
SCHEMBL4311822 0.90 AURKA (0.72) AURKAAURKBHTR1ADRD2HTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 — — EP claimed
EP-1847532-B1 IGF-1R INHIBITOR KYOWA HAKKO KIRIN CO LTD (JP) 2013-06-05 — — EP disclosed
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 AURKA 3687/4885AURKB 3438/4885HTR1A 526/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback